Single-fraction lung SBRT achieved 100% estimated one-year local control in selected patients
Single-fraction SBRT achieved 100% estimated 12-month local control without grade ≥3 toxicity in a selected 49-patient cohort.
Single-fraction SBRT achieved 100% estimated 12-month local control without grade ≥3 toxicity in a selected 49-patient cohort.
A circulation-based model predicted post-SBRT lymphocyte trajectories and linked a higher predicted lymphocyte nadir with better survival.
ELCC 2026 highlighted growing integration of SBRT and thoracic radiotherapy with targeted therapy, immunotherapy and biomarker-guided treatment selection.
Preoperative SBRT produced a pooled 21.4% pathological complete response rate, with irradiation-to-surgery interval strongly associated with response.
D95% and D98% PTV prescriptions produced substantial interpatient variability, while GTV- and ITV-based median or mean doses were more accurate.
Durvalumab, tremelimumab and SBRT produced 72.7% six-month progression-free survival in 33 patients with oligometastatic HNSCC.
ASTRO expands radiation therapy recommendations across locally advanced, recurrent and oligometastatic pancreatic cancer, with new guidance on dose escalation and adaptation.
A longitudinal CT radiomics model identified post-SBRT rib fracture risk with 85% sensitivity and 71% specificity in validation.
Across 40 Unity SBRT plans, OCTAVIUS 4D achieved 98.3% mean local gamma passing with sub-degree angular agreement.
Hydrogel spacers showed no meaningful loss of geometry during prostate SBRT, supporting stable rectal separation across the treatment course.
Eight of ten patients completed simulation-free single-fraction adaptive lung SBRT, with treatment taking a median 72 minutes.
DIR reduced estimated liver maximum dose from 123.8 to 83.2 Gy, but accuracy deteriorated markedly for bowel and stomach.
Empty-bladder SBRT was feasible in 85% of screened patients, with grade 2 or higher urinary toxicity of 28.1%.
Two-year local control reached 88%, but median progression-free survival was 5.8 months and systemic treatment changed after 4.4 months.
Seventy-three percent of failures after nonadherent sacral contouring involved sectors that guidelines recommended including in the clinical target volume.